AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2019
Jan 31, 2019
32134_dirs_2019-01-30_3b25672f-4ca1-44fd-9410-584d03e01782.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2019-01-28
Reporting Person: Nicholson John (SVP & Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-28 | Common Stock | M | 63000 | $10.69 | Acquired | 237477 | Direct |
| 2019-01-28 | Common Stock | S | 63000 | $42.82 | Disposed | 174477 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-28 | Stock Option | $10.69 | M | 63000 | Disposed | 2019-02-07 | Common Stock (63000) | Direct |
Footnotes
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Nicholson for certain options expiring on February 7, 2019.
F2: This transaction was executed in multiple trades at prices ranging from $42.31 to $43.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.